J Korean Med Assoc.  2016 Nov;59(11):866-871. 10.5124/jkma.2016.59.11.866.

Diagnosis and treatment of alopecia areata

• Lee Y

• KMID: 2358434
• DOI: http://doi.org/10.5124/jkma.2016.59.11.866

Abstract

Alopecia areata (AA) is a disease in which the patient experiences a sudden loss of scalp hair leaving round patches. It has a lifetime risk of 1.7%. AA is known to occur on any part of the body, including the scalp, beard area, axilla, and even the pubic area. Although the pathogenesis of AA is poorly understood, the consensus is that AA is an organ-specific autoimmune disease that typically presents in the hair follicles. Susceptibility to the development of AA may be modified by environmental factors, including exposure to pro-inflammatory agents and other modulators. The differentiation of AA can sometimes be challenging as several conditions (such as trichotillomania, tinea capitis, telogen effluvium, and lupus) may resemble AA. Obtaining the patient's history, performing a hair pull test, and skin biopsy or dermoscopic findings can be helpful for confirmation. Treatment for AA is usually based on patient age and the extent of hair loss, but there are no therapeutic agents that are curative or preventive for AA. AA can progress unpredictably. Indicators of poor prognosis include atopy, co-occurring immune diseases, positive family history, young age of onset, and ophiasis.

Keyword

Alopecia areata; Diagnosis; Prognosis; Therapeutics

MeSH Terms

Age of Onset
Alopecia Areata*
Alopecia*
Autoimmune Diseases
Axilla
Biopsy
Consensus
Diagnosis*
Hair
Hair Follicle
Humans
Immune System Diseases
Prognosis
Scalp
Skin
Tinea Capitis
Trichotillomania

Reference

1. Gollnick H, Orfanos CE. Alopecia areata: pathogenesis and clinical picture. In : Orfanos CE, Happle R, editors. Hair and hair diseases. 1st ed. Berlin: Springer Berlin;1990. p. 529–570.

2. Price VH. Alopecia areata: clinical aspects. J Invest Dermatol. 1991; 96:68S.

3. Wasserman D, Guzman-Sanchez DA, Scott K, McMichael A. Alopecia areata. Int J Dermatol. 2007; 46:121–131.

4. Nanda A, Al-Fouzan AS, Al-Hasawi F. Alopecia areata in children: a clinical profile. Pediatr Dermatol. 2002; 19:482–485.

5. Lee JC, Kim HY, Kim HJ, Kim BS, Lee WJ, Lee SJ, Kim DW. Long term follow-up study of corticosteroid-treated patients with alopecia areata. Korean J Dermatol. 2008; 46:465–472.

6. Kossard S. Lupus panniculitis clinically simulating alopecia areata. Australas J Dermatol. 2002; 43:221–223.

7. Grant JE, Chamberlain SR. Trichotillomania. Am J Psychiatry. 2016; 173:868–874.

8. Todes-Taylor N, Turner R, Wood GS, Stratte PT, Morhenn VB. T cell subpopulations in alopecia areata. J Am Acad Dermatol. 1984; 11(2 Pt 1):216–223.

9. Tobin DJ, Fenton DA, Kendall MD. Cell degeneration in alopecia areata: an ultrastructural study. Am J Dermatopathol. 1991; 13:248–256.

10. McElwee KJ, Freyschmidt-Paul P, Hoffmann R, Kissling S, Hummel S, Vitacolonna M, Zoller M. Transfer of CD8(+) cells induces localized hair loss whereas CD4(+)/CD25(-) cells promote systemic alopecia areata and CD4(+)/CD25(+) cells blockade disease onset in the C3H/HeJ mouse model. J Invest Dermatol. 2005; 124:947–957.

11. Paus R, Nickoloff BJ, Ito T. A ‘hairy’ privilege. Trends Immunol. 2005; 26:32–40.

12. Stankler L. Synchronous alopecia areata in two siblings: a possible viral aetiology. Lancet. 1979; 1:1303–1304.

13. McDonagh AJ, Tazi-Ahnini R. Epidemiology and genetics of alopecia areata. Clin Exp Dermatol. 2002; 27:405–409.

14. Lu W, Shapiro J, Yu M, Barekatain A, Lo B, Finner A, McElwee K. Alopecia areata: pathogenesis and potential for therapy. Expert Rev Mol Med. 2006; 8:1–19.

15. Akar A, Arca E, Erbil H, Akay C, Sayal A, Gur AR. Antioxidant enzymes and lipid peroxidation in the scalp of patients with alopecia areata. J Dermatol Sci. 2002; 29:85–90.

16. Tazi-Ahnini R, Cox A, McDonagh AJ, Nicklin MJ, di Giovine FS, Timms JM, Messenger AG, Dimitropoulou P, Duff GW, Cork MJ. Genetic analysis of the interleukin-1 receptor antagonist and its homologue IL-1L1 in alopecia areata: strong severity association and possible gene interaction. Eur J Immunogenet. 2002; 29:25–30.

17. Martinez-Mir A, Zlotogorski A, Gordon D, Petukhova L, Mo J, Gilliam TC, Londono D, Haynes C, Ott J, Hordinsky M, Nanova K, Norris D, Price V, Duvic M, Christiano AM. Genomewide scan for linkage reveals evidence of several susceptibility loci for alopecia areata. Am J Hum Genet. 2007; 80:316–328.

18. Betz RC, Petukhova L, Ripke S, Huang H, Menelaou A, Redler S, Becker T, Heilmann S, Yamany T, Duvic M, Hordinsky M, Norris D, Price VH, Mackay-Wiggan J, de Jong A, DeStefano GM, Moebus S, Bohm M, Blume-Peytavi U, Wolff H, Lutz G, Kruse R, Bian L, Amos CI, Lee A, Gregersen PK, Blaumeiser B, Altshuler D, Clynes R, de Bakker PI, Nothen MM, Daly MJ, Christiano AM. Genome-wide meta-analysis in alopecia areata resolves HLA associations and reveals two new susceptibility loci. Nat Commun. 2015; 6:5966.

19. McElwee K, Freyschmidt-Paul P, Ziegler A, Happle R, Hoffmann R. Genetic susceptibility and severity of alopecia areata in human and animal models. Eur J Dermatol. 2001; 11:11–16.

20. Rodriguez TA, Duvic M. National Alopecia Areata Registry. Onset of alopecia areata after Epstein-Barr virus infectious mononucleosis. J Am Acad Dermatol. 2008; 59:137–139.

21. Brajac I, Tkalcic M, Dragojevic DM, Gruber F. Roles of stress, stress perception and trait-anxiety in the onset and course of alopecia areata. J Dermatol. 2003; 30:871–878.

22. Gulec AT, Tanriverdi N, Duru C, Saray Y, Akcali C. The role of psychological factors in alopecia areata and the impact of the disease on the quality of life. Int J Dermatol. 2004; 43:352–356.

23. Alsantali A. Alopecia areata: a new treatment plan. Clin Cosmet Investig Dermatol. 2011; 4:107–115.

24. Alkhalifah A, Alsantali A, Wang E, McElwee KJ, Shapiro J. Alopecia areata update. Part II: treatment. J Am Acad Dermatol. 2010; 62:191–202.

25. Kuldeep C, Singhal H, Khare AK, Mittal A, Gupta LK, Garg A. Randomized comparison of topical betamethasone valerate foam, intralesional triamcinolone acetonide and tacrolimus ointment in management of localized alopecia areata. Int J Trichology. 2011; 3:20–24.

26. Tosti A, Piraccini BM, Pazzaglia M, Vincenzi C. Clobetasol propionate 0.05% under occlusion in the treatment of alopecia totalis/universalis. J Am Acad Dermatol. 2003; 49:96–98.

27. Fiedler-Weiss VC. Potential mechanisms of minoxidil-induced hair growth in alopecia areata. J Am Acad Dermatol. 1987; 16:653–656.

28. Messenger AG, Rundegren J. Minoxidil: mechanisms of action on hair growth. Br J Dermatol. 2004; 150:186–194.

29. Galbraith GM, Thiers BH. In vitro suppression of human lymphocyte activity by minoxidil. Int J Dermatol. 1985; 24:249–251.

30. Zawar VP, Karad GM. Liquid nitrogen cryotherapy in recalcitrant alopecia areata: a study of 11 patients. Int J Trichology. 2016; 8:15–20.

31. Jun M, Lee NR, Lee WS. Efficacy and safety of superficial cryotherapy for alopecia areata: a retrospective, comprehensive review of 353 cases over 22 years. J Dermatol. 2016; 10. 06. [Epub]. DOI: 10.1111/1346-8138.13613.

32. Chiang KS, Mesinkovska NA, Piliang MP, Bergfeld WF. Clinical efficacy of diphenylcyclopropenone in alopecia areata: retrospective data analysis of 50 patients. J Investig Dermatol Symp Proc. 2015; 17:50–55.

33. Im M, Lee SS, Lee Y, Kim CD, Seo YJ, Lee JH, Park JK. Prognostic factors in methylprednisolone pulse therapy for alopecia areata. J Dermatol. 2011; 38:767–772.

34. Kurosawa M, Nakagawa S, Mizuashi M, Sasaki Y, Kawamura M, Saito M, Aiba S. A comparison of the efficacy, relapse rate and side effects among three modalities of systemic corticosteroid therapy for alopecia areata. Dermatology. 2006; 212:361–365.

35. Olsen EA, Carson SC, Turney EA. Systemic steroids with or without 2% topical minoxidil in the treatment of alopecia areata. Arch Dermatol. 1992; 128:1467–1473.

36. Kim BJ, Min SU, Park KY, Choi JW, Park SW, Youn SW, Park KC, Huh CH. Combination therapy of cyclosporine and methylprednisolone on severe alopecia areata. J Dermatolog Treat. 2008; 19:216–220.

37. Garcia Bartels N, Lee HH, Worm M, Burmester GR, Sterry W, Blume-Peytavi U. Development of alopecia areata universalis in a patient receiving adalimumab. Arch Dermatol. 2006; 142:1654–1655.

38. Ettefagh L, Nedorost S, Mirmirani P. Alopecia areata in a patient using infliximab: new insights into the role of tumor necrosis factor on human hair follicles. Arch Dermatol. 2004; 140:1012.

39. Spano F, Donovan JC. Alopecia areata. Part 1: pathogenesis, diagnosis, and prognosis. Can Fam Physician. 2015; 61:751–755.